by Peter Ciszewski | Jun 14, 2021
Peter Langmuir, MD, Group Vice President, Oncology Targeted Therapeutics at Incyte, discusses interim data of a phase 2 study assessing the combination of ruxolitinib and parsaclisib in patients with myelofibrosis. Myelofibrosis is a rare cancer characterized...
by Peter Ciszewski | Jun 10, 2021
Mounzer Agha, MD, Director of the Mario Lemieux Center for Blood Cancers at UPMC Hillman Cancer Center and Clinical Director of the Hematopoietic Stem Cell Transplantation of UPMC, discusses data of Cohort A of the CARTITUDE-2 study. This study is evaluating...
by Peter Ciszewski | Jun 8, 2021
Meghann Ferguson, Director-at-Large at the National Niemann-Pick Disease Foundation and mother of a 7-year-old boy with Niemann-Pick Disease Type C (NPC), describes her son’s diagnostic journey. NPC is a disabling neurogenetic disorder that has been diagnosed...
by Peter Ciszewski | Jun 3, 2021
Rebecca Aune, Director of Education Programs for the National Organization for Rare Disorders (NORD), talks about the upcoming 2021 Living Rare, Living Stronger NORD Patient and Family Forum being held June 26-27. The event will be held virtually. As Ms. Aune...
by Peter Ciszewski | Jun 2, 2021
Quinn Dinh, MD, Vice President of Medical Affairs at Horizon Therapeutics, discusses what clinicians ought to know about neuromyelitis optica spectrum disorder (NMOSD). NMOSD is a rare central nervous disorder that primarily affects the spinal cord and optic...
